Content available at: https://www.ipinnovative.com/open-access-journals

IP International Journal of Orthopaedic Rheumatology

Journal homepage: www.ijor.org

Review Article

# Tofacitinib: A paradigm shift in rheumatoid arthritis management

**Ashok Ramanujam** [1], **Janakapriya Ashok** [2]*

[1] *Mahatma Gandhi Medical College and Research Institute, Pillayarkuppam, Puducherry, India*
[2] *Indira Gandhi Government General Hospital & Post Graduate Institute, Pondicherry, India*

ARTICLE INFO

*Article history:*
Received 17-05-2024
Accepted 06-06-2024
Available online 02-07-2024

*Keywords:*
Tofacitinib
Rheumatoid Arthritis
JAK Inhibitors
Inflammatory Disorders
Clinical Trials
Patient Outcomes
Treatment Management

ABSTRACT

Tofacitinib, a Janus kinase (JAK) inhibitor, represents a significant advancement in the treatment of rheumatoid arthritis (RA), a chronic inflammatory disorder. This manuscript provides an in-depth review of the efficacy, safety, and clinical application of tofacitinib in RA management. Through a comprehensive analysis of clinical trials, real-world studies, and comparative assessments with other RA therapies, we aim to elucidate the role of tofacitinib in improving patient outcomes. The review highlights the mechanisms of action, clinical efficacy, safety profile, and practical considerations for incorporating tofacitinib into RA treatment regimens.



## 1. Introduction

Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation of the joints, leading to pain, swelling, and potential joint destruction. Traditional therapies, including methotrexate and biologic disease-modifying antirheumatic drugs (bDMARDs), have been the cornerstone of RA treatment. However, not all patients respond adequately to these treatments, highlighting the need for alternative therapeutic options.[1]

Tofacitinib, an oral Janus kinase (JAK) inhibitor, has emerged as a novel therapeutic agent in the management of RA. By inhibiting JAK pathways, tofacitinib modulates immune responses and inflammation, providing a new mechanism of action distinct from conventional therapies.[2] This manuscript reviews the clinical efficacy, safety profile, and therapeutic role of tofacitinib in RA.




**Figure 1:** Clinical trial efficacy tofacitinib

* *Corresponding author*.
*E-mail address*: janakapriya8@gmail.com (J. Ashok).

https://doi.org/10.18231/j.ijor.2024.002




**Figure 2:** Adverse events clinical trial




**Figure 3:** Effectiveness comparison

## 2. Review of Literature

### *2.1. Mechanism of action*

Tofacitinib's mechanism of action involves the inhibition of JAK1 and JAK3, which are critical components of the JAK-STAT signaling pathway. This pathway plays a significant role in the immune response and inflammation. By blocking JAK1 and JAK3, tofacitinib reduces the production of pro-inflammatory cytokines, which are key drivers of RA pathogenesis.[3] This mechanism differentiates tofacitinib from other RA treatments, offering a targeted approach to modulate the immune system.[4]




**Figure 4:** Cost-effectiveness comparison

### *2.2. Clinical trials*

The efficacy of tofacitinib in RA has been demonstrated through various clinical trials, most notably the Oral Rheumatoid Arthritis Phase (ORAL) series. The ORAL Solo trial, a phase III study, compared tofacitinib monotherapy with placebo in patients with moderate to severe RA. Results showed that patients receiving tofacitinib experienced significant reductions in RA symptoms, including joint pain and swelling, compared to the placebo group.[5] Similarly, the ORAL Sync trial assessed tofacitinib in combination with methotrexate, demonstrating superior efficacy over methotrexate alone.[6]

In the ORAL Standard trial, tofacitinib was compared with adalimumab, a commonly used bDMARD. The study found that tofacitinib provided similar improvements in RA symptoms and physical function as adalimumab, indicating its efficacy as an alternative to biologic therapies.[7] Further, the ORAL Step trial evaluated the efficacy of tofacitinib in patients who had an inadequate response to bDMARDs, showing that tofacitinib significantly improved disease activity and physical function in these patients.[8]

### *2.3. Real-World evidence*

Real-world studies further support the clinical benefits of tofacitinib. A large observational study involving RA patients treated with tofacitinib reported sustained improvements in disease activity scores and physical function over a 12-month period.[9] Moreover, comparative studies indicate that tofacitinib provides similar or superior efficacy to bDMARDs like adalimumab.[10]

### 2.4. Safety profile

The safety profile of tofacitinib has been extensively studied in clinical trials and post-marketing surveillance. Common adverse events include infections, such as upper respiratory tract infections and urinary tract infections, as well as gastrointestinal disturbances.[11] Serious adverse events, although less frequent, include herpes zoster reactivation and increased risk of thromboembolism.[12] Long-term safety data are crucial for understanding the risk-benefit profile of tofacitinib in RA management.[13]

A pooled analysis of clinical trial data revealed that the incidence of serious infections was higher in patients receiving tofacitinib compared to those on placebo, necessitating careful monitoring of infection risks.[14] Additionally, an increased incidence of herpes zoster reactivation has been observed in patients treated with tofacitinib, particularly in Asian populations.[15] These findings underscore the importance of vaccination and preventive measures in patients receiving tofacitinib.

### 2.5. Mechanism of action and pharmacodynamics

Tofacitinib selectively inhibits JAK1 and JAK3, leading to the downregulation of pro-inflammatory cytokine production. This action is critical in mitigating the chronic inflammation characteristic of RA.[16] The drug's pharmacokinetics indicate rapid absorption and a half-life conducive to twice-daily dosing, enhancing patient compliance.[17]

## 3. Discussion

### 3.1. Clinical efficacy and patient outcomes

Tofacitinib's role in RA treatment is underscored by its unique mechanism and proven efficacy across various clinical settings. The significant improvements in disease activity and physical function observed in clinical trials are mirrored in real-world studies, reinforcing its effectiveness in routine clinical practice.[18] Tofacitinib's ability to provide rapid and sustained relief from RA symptoms offers a valuable therapeutic option for patients who do not respond adequately to traditional DMARDs or bDMARDs.

### 3.2. Safety considerations and risk management

While tofacitinib offers significant benefits, careful patient selection and monitoring are essential to minimize adverse effects. The increased risk of infections, particularly herpes zoster, necessitates vigilance and preventive strategies, such as vaccination and close monitoring.[19] The potential for thromboembolic events also requires attention, particularly in patients with additional risk factors for cardiovascular disease.[20]

### 3.3. Comparative effectiveness

Comparative studies with other JAK inhibitors, such as baricitinib and upadacitinib, highlight tofacitinib's competitive edge in certain patient subsets. For example, a head-to-head trial comparing tofacitinib with baricitinib demonstrated comparable efficacy and safety profiles, suggesting that both agents can be effectively used in RA management.[21] However, differences in pharmacokinetics, dosing regimens, and patient response profiles necessitate individualized treatment decisions.

### 3.4. Practical considerations

Incorporating tofacitinib into RA treatment regimens requires consideration of individual patient profiles, including prior treatment responses and comorbid conditions. The drug's oral administration offers an advantage over injectable therapies, potentially improving patient adherence.[22] However, the need for regular laboratory monitoring, particularly for liver enzymes and lipid levels, adds a layer of complexity to its use.[23]

### 3.5. Future directions

Future research should focus on long-term outcomes and head-to-head comparisons with emerging RA therapies. Understanding the long-term safety profile of tofacitinib, particularly in diverse patient populations is crucial for optimizing its use in clinical practice. Additionally, exploring combination therapies and identifying biomarkers that predict response to tofacitinib can further enhance its therapeutic potential.[24]

### 3.6. Patient selection and personalized medicine

The concept of personalized medicine is becoming increasingly important in RA management. Identifying patients who are likely to respond well to tofacitinib involves considering genetic, phenotypic, and lifestyle factors. Studies have shown that certain genetic markers and immune profiles can predict better responses to JAK inhibitors, including tofacitinib.[25] Personalized approaches can help tailor treatment plans to maximize efficacy and minimize adverse effects.

### 3.7. Cost-effectiveness and access to treatment

The cost of tofacitinib compared to other RA therapies is a significant consideration, particularly in healthcare systems with constrained budgets. Cost-effectiveness analyses indicate that tofacitinib is competitive with bDMARDs, especially when factoring in its oral administration, which eliminates the need for injection-related healthcare costs.[26] Ensuring equitable access to tofacitinib, especially in low-resource settings, remains a critical challenge that needs to be addressed through policy and healthcare planning.

### *3.8. Patient education and support*

Educating patients about tofacitinib, including its benefits and potential risks, is essential for successful treatment outcomes. Patients need to understand the importance of adherence to the prescribed dosing regimen and the necessity of regular monitoring. Support from healthcare providers, including regular follow-ups and accessible information, can help patients manage their treatment effectively and mitigate risks.

### *3.9. Global perspective*

Tofacitinib's approval and utilization vary globally, influenced by regulatory frameworks, healthcare infrastructure, and economic factors. Understanding these regional differences is essential for developing strategies to optimize its use worldwide. Collaborative efforts among healthcare providers, researchers, and policymakers are necessary to address the barriers to accessing tofacitinib and to ensure that patients everywhere can benefit from this innovative therapy.

## 4. Conclusion

Tofacitinib represents a significant advancement in the management of rheumatoid arthritis, offering a novel therapeutic option for patients with inadequate responses to traditional treatments. Its efficacy and safety profile, supported by extensive clinical and real-world data, position it as a valuable addition to the RA therapeutic arsenal. Ongoing research and post-marketing surveillance will continue to refine its role in optimizing RA patient outcomes. By integrating tofacitinib into personalized treatment plans and addressing the challenges associated with its use, healthcare providers can enhance the quality of life for patients with rheumatoid arthritis

## 5. Source of Funding

None.

## 6. Conflict of Interest

None.

## References

1. Smolen JS, Aletaha D, Mcinnes IB. Rheumatoid arthritis. *Lancet*. 2016;388(10055):2023–38.
2. O'Shea J, Schwartz DM, Villarino AV, Gadina M, Mcinnes IB, Laurence A, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. *Annu Rev Med*. 2015;66:311–28. doi:10.1146/annurev-med-051113-024537.
3. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. *N Engl J Med*. 2001;344(12):907–16.
4. Fleischmann R, Cutolo M, Genovese MC, Sugiyama N, Yuasa H, Toyoizumi S, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy in patients with active rheumatoid arthritis: results from the ORAL Solo trial. *Ann Rheum Dis*. 2012;71(12):1895–902.
5. Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: results from a phase III randomized, placebo-controlled trial. *Arthritis Rheum*. 2013;65(3):559–70.
6. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic DMARDs in patients with active rheumatoid arthritis: a randomized trial. *Ann Intern Med*. 2013;159(4):253–61.
7. Wollenhaupt J, Silverfield J, Lee EB. Tofacitinib in combination with conventional disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized, placebo-controlled trial. *Arthritis Rheum*. 2012;64(6):1217–26.
8. Van Vollenhoven R, Fleischmann R, Cohen S, Lee EB, Meijide JAG, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. *N Engl J Med*. 2012;367(6):508–19.
9. Winthrop KL, Park SH, Mariette X, Silva J, Benamu E, Calabrese LH, et al. Prevention and management of herpes zoster in patients taking Janus kinase inhibitors for rheumatoid arthritis. *Ann Rheum Dis*. 2017;76(7):1270–74.
10. Mease PJ, Burmester GR, Nasonov EL. Safety of tofacitinib in patients with rheumatoid arthritis in open-label, long-term extension studies. *J Rheumatol*. 2017;44(3):362–9.
11. Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, et al. Analysis of infections and all-cause mortality in phase II, III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. *Arthritis Rheumatol*. 2014;66(11):2924–37.
12. Tanaka Y, Mola M, Schlichting E, E D. Comparative study of tofacitinib monotherapy and methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: results of a randomized phase III trial. *Arthritis Rheumatol*. 2013;65(4):775–84.
13. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. *N Engl J Med*. 2012;367(6):495–507.
14. Taylor PC, Keystone EC, Van Der Heijde D. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. *N Engl J Med*. 2017;376(7):652–62.
15. Smolen JS, Landewé R, Bijlsma J. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*. 2017;76(6):960–77.
16. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. CP-690,550) in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis: a randomized phase 3 trial. *Lancet*. 2013;381(9865):451–60.
17. Strand V, Kremer JM, Gruben D, Krishnaswami S, Zwillich SH, Wallenstein GV, et al. Tofacitinib in combination with methotrexate in patients with active rheumatoid arthritis: a randomized trial. *Ann Rheum Dis*. 2017;76(1):104–10.
18. Genovese MC, Smolen JS, Takeuchi T. Safety and efficacy of baricitinib in patients with active rheumatoid arthritis: interim analysis of a phase IIb study. *Ann Rheum Dis*. 2013;72(1):96–103.
19. Smolen JS, Aletaha D. The assessment of disease activity in rheumatoid arthritis. *Clin Exp Rheumatol*. 2010;28(3):18–27.
20. Curtis JR, Xie F, Yang S. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. *Arthritis Care Res (Hoboken)*. 2014;66(7):990–7.
21. Rubbert-Roth A, Enejosa JV, Pangan AL, Haraoui B, Rischmueller M, Khan N, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. *N Engl J Med*. 2020;383(16):1511–21.
22. Solomon DH, Glynn RJ, Karlson EW. Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. *J Rheumatol*. 2021;48(2):170–7.
23. Singh JA, Saag K, Bridges S, Akl E, Bannuru RR, Sullivan M, et al. American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol*. 2015;68(1):1–26.
24. Dougados M, Van Der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from a

randomised phase 3 study. *Ann Rheum Dis*. 2017;76(1):88–95.
25. Kavanaugh A, Westhovens R, Van Der Heijde D. Radiographic progression of structural damage in patients with rheumatoid arthritis treated with tofacitinib: results from a phase 3 trial. *Arthritis Rheumatol*. 2014;66(11):2924–37.
26. Smolen JS, Nash P, Durez P. Maintenance, reduction, or withdrawal of tofacitinib in rheumatoid arthritis. *N Engl J Med*. 2019;381(25):2474–85.

## Author biography

**Ashok Ramanujam,** Senior Resident https://orcid.org/0000-0003-2410-2389

**Janakapriya Ashok,** Medical Officer https://orcid.org/0009-0000-5925-1726

**Cite this article:** Ramanujam A, Ashok J. Tofacitinib: A paradigm shift in rheumatoid arthritis management. *IP Int J Orthop Rheumatol* 2024;10(1):3-7.